Allison Bratzel

Stock Analyst at Piper Sandler

Total Price Targets

8

Stocks Covered

4

Sectors

Healthcare

Most Recent

Mar 4, 2026

Notable Calls (Last 12 Months)

Most Bullish

AKBA+189.9%
Akebia Therapeutics, Inc.
$4.00 targetFeb 6, 2026
SRRK+51.1%
Scholar Rock Holding Corporation
$51.00 targetSep 24, 2025
SRRK+29.3%
Scholar Rock Holding Corporation
$58.00 targetMar 4, 2026

Most Bearish

Stocks Covered by Allison Bratzel

Symbol	Company	Latest Target	Current Price	Upside	# Targets	Last Updated
SRRK	Scholar Rock Holding Corporation	$58.00	$46.75	+24.1%	4	Mar 4, 2026
AKBA	Akebia Therapeutics, Inc.	$4.00	$1.41	+183.7%	1	Feb 6, 2026
INCY	Incyte Corporation	$110.00	$96.41	+14.1%	2	Feb 6, 2026
ROIV	Roivant Sciences Ltd.	$20.00	$28.06	-28.7%	1	May 31, 2024

Recent Activity

Mar 4, 2026— Set$58.00price target onSRRK(Scholar Rock Holding Corporation)
Feb 6, 2026— Set$110.00price target onINCY(Incyte Corporation)
Feb 6, 2026— Set$4.00price target onAKBA(Akebia Therapeutics, Inc.)
Nov 4, 2025— Set$102.00price target onINCY(Incyte Corporation)
Sep 24, 2025— Set$51.00price target onSRRK(Scholar Rock Holding Corporation)
Oct 15, 2024— Set$42.00price target onSRRK(Scholar Rock Holding Corporation)
May 31, 2024— Set$20.00price target onROIV(Roivant Sciences Ltd.)
May 23, 2024— Set$28.00price target onSRRK(Scholar Rock Holding Corporation)

Frequently Asked Questions

Who is Allison Bratzel?

Allison Bratzel is a stock analyst at Piper Sandler covering 4 stocks primarily in Healthcare. They have issued 8 price targets since May 23, 2024.

What stocks does Allison Bratzel cover?

Allison Bratzel currently covers 4 stocks, including SRRK, INCY, AKBA, ROIV.

What is Allison Bratzel's latest price target?

Allison Bratzel's most recent price target was $58.00 on SRRK (Scholar Rock Holding Corporation), set on Mar 4, 2026.

What is Allison Bratzel's highest price target?

Allison Bratzel's highest issued price target is $110.00 on INCY, set on Feb 6, 2026.

More Analysts at Piper Sandler

Thomas Champion

Coverage based on publicly published price targets. Not investment advice.